| Unique ID issued by UMIN | UMIN000063668 |
|---|---|
| Receipt number | R000072871 |
| Scientific Title | Long-term outcomes of four-fraction carbon-ion radiotherapy for intermediate-risk prostate cancer: A Phase I/II dose-escalation trial |
| Date of disclosure of the study information | 2026/11/17 |
| Last modified on | 2026/11/17 19:23:08 |
Long-term outcomes of four-fraction carbon-ion radiotherapy for intermediate-risk prostate cancer: A Phase I/II dose-escalation trial
Long-term Outcomes of Four-Fraction CIRT for Intermediate-Risk Prostate Cancer
Long-term outcomes of four-fraction carbon-ion radiotherapy for intermediate-risk prostate cancer: A Phase I/II dose-escalation trial
Long-term Outcomes of Four-Fraction CIRT for Intermediate-Risk Prostate Cancer
| Japan |
Prostate cancer
| Urology | Radiology |
Malignancy
NO
We performed a long-term analysis of intermediate-risk patients enrolled in the trial.
Efficacy
5-year biochemical recurrence-free survival (bRFS) rate
Observational
| Not applicable |
| Not applicable |
Male
Patients enrolled in the previous Phase I/II trial of four-fraction carbon-ion radiotherapy for low- or intermediate-risk localized prostate cancer.
Patients who or whose legally authorized representatives declined the use of their clinical data for this study.
60
| 1st name | Atsushi |
| Middle name | |
| Last name | Okato |
QST Hospital, National Institutes for Quantum Science and Technology
Department of Genitourinary Oncology
263-8555
4-9-1 Anagawa, Inage-ku, Chiba
043-206-3306
okato.atsushi@qst.go.jp
| 1st name | Atsushi |
| Middle name | |
| Last name | Okato |
QST Hospital, National Institutes for Quantum Science and Technology
Department of Genitourinary Oncology
263-8555
4-9-1 Anagawa, Inage-ku, Chiba
043-206-3306
okato.atsushi@qst.go.jp
QST Hospital, National Institutes for Quantum Science and Technology
Ministry of Education, Culture, Sports, Science and Technology (MEXT)
Japanese Governmental office
National Institutes for Quantum Science and Technology Certified Review Board
4-9-1 Anagawa, Inage-ku, Chiba
043-206-3306
helsinki@qst.go.jp
NO
| 2026 | Year | 11 | Month | 17 | Day |
Unpublished
Preinitiation
| 2026 | Year | 09 | Month | 28 | Day |
| 2026 | Year | 10 | Month | 15 | Day |
| 2026 | Year | 12 | Month | 01 | Day |
| 2027 | Year | 12 | Month | 31 | Day |
This is a single-center, retrospective observational study involving 60 patients enrolled in a previous Phase I/II trial of four-fraction carbon-ion radiotherapy for low- or intermediate-risk localized prostate cancer.
Existing clinical data, including electronic medical records, will be retrospectively reviewed to evaluate the long-term efficacy and safety of four-fraction carbon-ion radiotherapy. The primary endpoint is the 5-year biochemical recurrence-free survival rate. Secondary endpoints include the 5-year overall survival rate, acute and late adverse events, and quality of life.
No additional therapeutic intervention will be performed in this study.
| 2026 | Year | 11 | Month | 17 | Day |
| 2026 | Year | 11 | Month | 17 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000072871